MSB 7.69% $1.19 mesoblast limited

Ann: FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L, page-1002

  1. 1,896 Posts.
    lightbulb Created with Sketch. 489
    I would think Sandra Finestone (PsyD (Acting Consumer Rep)' Executive Director - Association of Cancer Patient Educators
    Her primary focus is to ensure that the patient voice is always part of the research environment") and her opinion would hold more weight than random lawyer acting for anonymous clients evidently with nefarious intentions.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.